John Dingell

If you please, Mr. Meyer?

Do you believe that current industry efforts to protect consumer privacy are sufficient?

Mr. Chairman, I appreciate your courtesy and I commend you for this hearing.

By the way, thank you for your cooperation. No disrespect is intended here.

I believe so but I will have to submit something to you on that to make sure.

I don't believe so, no. I believe that I have a lot of faith in the regions.

One, does Order 1000 provide subsidies for renewable energy or transmission lines to carry renewable energy? Please answer yes or no.

So we have agreement there.

Madam Chairman, thank you. I commend you for this hearing.

I believe strongly we must address the rising issue of children obesity in this country.

I happen to agree with that, and I happen to have been a strong supporter of that.

The process by which we arrive at good standards is a matter of great importance to me.

You have not done so. We find that this gives us real problems in terms of understanding what is to be done or should be done.

How do you assure us that these voluntary guidelines will not become grafted into the law?

Like everybody in this room, I am troubled about children's nutrition.

At the end of the day, American consumers and patients are facing 3 problems: 1) the drugs, they need to be available and affordable; 2) are there drugs they need safe; and 3) are they efficacious? Do they work?

Do you have authority at FDA or at HHS to waive any of the requirements with regard to efficacy, good manufacturing practices, or safety, yes or no, in the event of shortage?

I have got some legislation to address that and I hope that we will be shortly addressing it here in this committee.

I believe that agency has documented that fact over the course of 3 years and two administrations, one of each, Republican and Democratic.

I hope that we don't take the failure, for whatever reason, of this project to mean that all renewable energy projects are bad investments.

This is a matter on which I have worked with the gentleman, my colleague Mr. Shimkus.

It is my understanding that the FDA has been working to address shortages of medically necessary drugs.

I have a bill that would require manufacturers to maintain records establishing where the drug and its raw materials were produced.

I think it would require the American people to be kept in the dark about what is happening to their health and about what is clean air.

Mr. Chairman, thank you for your courtesy.